Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

about

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.Cholestatic liver diseases: new targets, new therapies

P2860

Q55190939-75175B25-2A54-4333-9DFE-DE34162A1CFA Q57111104-4EB25D05-5F90-468D-967D-2B4237554D1F

P2860

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

Item

http://www.wikidata.org/entity/Q47615113

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response.

@en

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response.

@nl

type

Item

label

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response.

@en

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response.

@nl

prefLabel

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response.

@en

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response.

@nl

P1476

Effects of Bezafibrate on Outc ...... Ursodeoxycholic Acid Response

@en

P2093

Anna Reig

http://www.w3.org/2001/XMLSchema#string

Pilar Sesé

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

The 5-D itch scale: a new measure of pruritus.

Fibrates and cholestasis

PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Novel Treatment Strategies for Primary Biliary Cholangitis.

Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.

Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.

P304

49-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2017.287

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Albert Pares

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29016567

http://www.w3.org/2001/XMLSchema#string

P921

cholangitis

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

about

P2860

P2860

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921